Is Sarepta Therapeutics (SRPT) Starting To Look Interesting Again After Recent Share Price Rebound

• Investors may be wondering if Sarepta Therapeutics at around US$22.80 is starting to look interesting again, or if the risks still dominate the story.
• The stock has recently posted an 11.3% return over 7 days and 36.4% over 30 days, although the 1-year return sits at a 56.5% decline and the 3-year return at an 83.8% decline, with a 67.1% decline over 5 years and a 7.0% return year to date.
• These moves have put Sarepta back on many watchlists as investors reassess the balance between long term potential and past volatility. Recent coverage has focused on how sentiment around the company, its product pipeline, and the broader biotech sector context may be shaping expectations and risk appetite.
• Right now, Sarepta has a valuation score of 4/6, which means it screens as undervalued on four of six checks. The next sections will walk through the main valuation methods behind that score and then finish with a more holistic way to think about what the market might be pricing in.

Find out why Sarepta Therapeutics's -56.5% return over the last year is lagging behind its peers.

Approach 1: Sarepta Therapeutics Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model projects a company’s future cash flows and then discounts them back to today’s value, giving an estimate of what the business might be worth per share based on those projected dollars.

For Sarepta Therapeutics, the model used is a 2 Stage Free Cash Flow to Equity approach. The latest twelve month free cash flow is a loss of $305.09 million, so the story here hinges on future cash generation rather than current profits. Analyst and extrapolated projections, provided by Simply Wall St, point to free cash flow of $353 million in 2026, rising through the forecast period to an estimated $466 million in 2030, all in $ and all below $1b, so still in the hundreds of millions range.

When those projected cash flows are discounted back to today using the DCF model, the resulting intrinsic value is about $76.31 per share. Compared with the recent share price around $22.80, the model implies Sarepta trades at roughly a 70.1% discount, which screens as significantly undervalued on this metric.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Sarepta Therapeutics is undervalued by 70.1%. Track this in your watchlist or portfolio, or discover 62 more high quality undervalued stocks.

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Sarepta Therapeutics.

Approach 2: Sarepta Therapeutics Price vs Sales

For companies where earnings are not yet positive or are highly volatile, the P/S ratio is often a more practical valuation tool than P/E. It looks at how much investors are paying for each dollar of revenue, which can be especially useful for biotech names that are still working toward consistent profitability.

In general, higher growth potential and lower perceived risk tend to justify a higher P/S multiple, while slower growth and higher risk usually support a lower, more conservative multiple. Sarepta Therapeutics currently trades on a P/S ratio of 1.09x. This is well below the Biotechs industry average P/S of 11.11x and the peer group average of 12.45x.

Simply Wall St’s Fair Ratio for Sarepta is 0.88x. This is a proprietary estimate of what a reasonable P/S multiple could be for the company after accounting for factors such as earnings growth, industry, profit margins, market capitalization and specific risks. Because it is tailored to the company’s profile, the Fair Ratio can be more informative than a simple comparison with peers or the broad industry. With the current 1.09x P/S compared with a Fair Ratio of 0.88x, the shares screen as somewhat expensive on this metric.

Result: OVERVALUED

P/S ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your Sarepta Therapeutics Narrative

Earlier it was mentioned that there is an even better way to think about valuation, and that is through Narratives. Narratives let you attach a clear story about Sarepta Therapeutics to concrete numbers like your own fair value, revenue, earnings and margin expectations, then see how that story stacks up against the current price.

A Narrative on Simply Wall St is essentially your thesis written into a simple forecast, so that your view of ELEVIDYS demand, LGMD and siRNA opportunities, safety and regulatory risk, and future profitability is translated into an explicit fair value that you can compare directly with the live share price to help decide whether Sarepta looks priced above or below your expectations.

These Narratives live inside the Community section on the platform, are used by millions of investors and update automatically when new earnings, clinical data, guidance or news are reflected in the underlying models. This means your fair value view stays aligned with the latest information rather than becoming stale.

For Sarepta today, one investor might anchor on a lower fair value close to the US$5 analyst low target because they focus on safety concerns and execution risk. Another might lean toward a higher fair value near US$209 because they are more optimistic about ELEVIDYS, DM1 and broader gene therapy adoption. Narratives help you see exactly which assumptions separate those two views.

For Sarepta Therapeutics, however, we will make it really easy for you with previews of two leading Sarepta Therapeutics Narratives:

🐂 Sarepta Therapeutics Bull Case

Fair value in this bullish narrative: US$40.10 per share.

At the recent US$22.80 share price, that is about 43.2% below this narrative fair value.

Modeled long run revenue trend in this view is an 11.32% annual decline.

• Emphasis on growing genetic testing, payer acceptance and expanded infusion capacity as key supports for Sarepta’s gene therapy portfolio.
• Analysts behind this view model a move from a small loss today to earnings of US$713.6m by around 2028, with margins rising into the high 30% range.
• This camp sees a path to a higher earnings base and applies a P/E below the current US Biotechs industry level to reach a bullish fair value.

🐻 Sarepta Therapeutics Bear Case

Fair value in this more cautious narrative: US$21.65 per share.

At the recent US$22.80 share price, that is about 5.3% above this narrative fair value.

Modeled long run revenue trend in this view is a 13.30% annual decline.

• Focus on safety concerns around ELEVIDYS, administrative delays and treatment bottlenecks that could slow revenue recognition.
• Analysts in this camp model earnings reaching US$87.3m by about 2029, with margins improving but staying in single digits.
• This view assumes Sarepta would trade on a P/E of 39.8x those earnings, which is higher than the current US Biotechs industry P/E, and still lands close to today’s share price.

Together, these two Narratives frame the current debate around Sarepta in a concrete way, so you can decide which set of assumptions looks closer to your own expectations and where you would place the fair value line for the stock.

See what the community is saying about Sarepta Therapeutics

Do you think there's more to the story for Sarepta Therapeutics? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com